Stoke Therapeutics (STOK) Retained Earnings (2018 - 2026)

Stoke Therapeutics' Retained Earnings history runs 9 years deep, the most recent figure standing at -$115000.0 for Q1 2026.

• On a quarterly basis, Retained Earnings rose 99.97% year-over-year to -$115000.0 in Q1 2026; TTM through Mar 2026 was -$115000.0, a 99.97% increase from a year earlier, with the FY2025 full-year figure at $543000.0, down 99.92% from the prior year.
• Retained Earnings fell to -$115000.0 in Q1 2026 per STOK's latest filing, from $543000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $720.0 million in Q4 2024 and bottomed at -$439.8 million in Q3 2025.
• The 5-year median for Retained Earnings is -$24000.0 (2023), against an average of $54.1 million.
• Across the five-year window, Retained Earnings slumped 1233968.18% in 2022 and soared 3000087.5% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$1.2 million in 2022, then jumped by 97.96% to -$24000.0 in 2023, then surged by 3000087.5% to $720.0 million in 2024, then tumbled by 99.92% to $543000.0 in 2025, then tumbled by 121.18% to -$115000.0 in 2026.
• Per Business Quant, the three latest STOK Retained Earnings figures stand at -$115000.0 (Q1 2026), $543000.0 (Q4 2025), and -$439.8 million (Q3 2025).